Marion C.
- Country
- France
- Department
- Hepato-gastroenterology
Research Overview
- Phase II Randomized Trial of Modified FOLFIRINOX and FOLFOX Regimens in Locally Advanced or Metastatic Small Bowel Adenocarcinoma
- Phase III Multicentric Study on Chemotherapy Efficacy in Stage III Colorectal Cancer with Positive ctDNA Post-Surgery Using Irinotecan and Drug Combination
- Efficacy and Safety of Zolbetuximab with Nab-Paclitaxel and Gemcitabine in Claudin 18.2 Positive Metastatic Pancreatic Adenocarcinoma
Data & Insights
Has run more than one trial at 165 of 323 partner sites.
Specializations
Colorectal Cancer Research
The investigator specializes in advanced approaches to colorectal cancer treatment, with particular emphasis on ctDNA-guided therapy decisions for both colon and rectal cancers.
- Stage II and III Colon Cancer Management
- Minimal Residual Disease Monitoring
- BRAF V600E Mutation Treatment
Expertise extends to innovative neoadjuvant strategies for locally advanced rectal cancer, particularly in cases with specific molecular characteristics.
Gastrointestinal Oncology
Focus on developing personalized treatment approaches for various gastrointestinal cancers, including specialized protocols for rare conditions.
- Pancreatic Adenocarcinoma Treatment
- Gastric Cancer Immunotherapy
- Small Bowel Adenocarcinoma Management
Additional expertise in chemotherapy optimization for patients with specific enzyme deficiencies affecting treatment metabolism.
Precision Medicine Applications
Specializes in molecular-guided treatment strategies across gastrointestinal cancers, incorporating advanced diagnostic techniques.
- Biomarker-Driven Treatment Selection
- Targeted Therapy Assessment
- Personalized Dosing Strategies
Expertise in adapting treatment protocols based on specific genetic and molecular markers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.